TP53 and lung adenocarcinoma: One study examined three distinct subtypes of KRAS-driven lung adenocarcinoma; the KL subtype which in addition to the KRAS mutation also has a comutation in STK11/LKB1, the KP subtype which has a comutation in TP53, and the K-only subtype which does not have a comutation in either of the tumour suppressor genes STK11/LKB1 or TP53. Out of these three subtypes, it was found that the KL subtype was associated with reduced objective response rate and progression-free survival following anti-PD-1 treatment [50].